Wolverine Trading
PLX icon

Wolverine Trading’s Protalix BioTherapeutics PLX Stock Holding History

Wolverine Trading’s Portfolio PLX Stock Details PLX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q2 		– Sell
-11,700
Closed -$30.2K – 5387
2025
Q1 		$30.2K Buy
+11,700
New +$27.9K ﹤0.01% 4513
2024
Q1 		– Sell
-32,100
Closed -$57.1K – 5096
2023
Q4 		$57.1K Buy
+32,100
New +$49.9K ﹤0.01% 4224
2023
Q3 		– Sell
-141,900
Closed -$308K – 4951
2023
Q2 		$308K Buy
+141,900
New +$338K ﹤0.01% 3062
2023
Q1 		– Sell
-13,000
Closed -$18K – 4782
2022
Q4 		$18K Buy
+13,000
New +$14.3K ﹤0.01% 3751
2022
Q3 		– Sell
-12,000
Closed -$13K – 5161
2022
Q2 		$13K Buy
+12,000
New +$14K ﹤0.01% 4293
2022
Q1 		– Sell
-22,700
Closed -$19K – 6208
2021
Q4 		$19K Sell
22,700
-52,200
-70% -$54.7K ﹤0.01% 5505
2021
Q3 		$103K Buy
74,900
+1,100
+1% +$1.67K ﹤0.01% 5753
2021
Q2 		$141K Buy
73,800
+54,900
+290% +$189K ﹤0.01% 5231
2021
Q1 		$85K Buy
+18,900
New +$88K ﹤0.01% 5495
2020
Q4 		– Sell
-11,800
Closed -$46K – 5311
2020
Q3 		$46K Buy
+11,800
New +$42.7K ﹤0.01% 4289
2020
Q2 		– Sell
-23,300
Closed -$55K – 5085
2020
Q1 		$55K Buy
+23,300
New +$77K ﹤0.01% 4224
2018
Q4 		– Sell
-1,430
Closed -$10K – 5129
2018
Q3 		$10K Buy
+1,430
New +$7.18K ﹤0.01% 4811
2017
Q4 		– Sell
-2,630
Closed -$15K – 5356
2017
Q3 		$15K Buy
+2,630
New +$16.8K ﹤0.01% 4315

Other funds holding PLX

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
OM
Opaleye Management Boston, Massachusetts $759M AUM 124.8% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
SWP
Stratos Wealth Partners Beachwood, Ohio $8.8B AUM 21.82% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Connor, Clark & Lunn Investment Management (CC&L)
Connor, Clark & Lunn Investment Management (CC&L) Vancouver, British Columbia, Canada $43.4B AUM 51.29% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

Wolverine Trading's PLX Position: Q3 2025 in Review

Wolverine Trading increased its Protalix BioTherapeutics (PLX) stake by 187% in Q3 2025, buying an estimated $74.7K and bringing the position to 70,394 shares worth $152K. The position accounts for ﹤0.01% of the portfolio, ranked #5054.

Wolverine Trading first reported a position in PLX in Q1 2018 and has held it in 9 quarters since. 77 funds tracked by Wall St. Rank hold PLX as of Q3 2025.

  • Wolverine Trading held 70,394 shares of Protalix BioTherapeutics worth $152K as of Q3 2025.
  • Wolverine Trading bought 45,886 Protalix BioTherapeutics shares in Q3 2025, an estimated $74.7K.
  • Protalix BioTherapeutics made up ﹤0.01% of Wolverine Trading's portfolio in Q3 2025, its #5054 holding.
  • Wolverine Trading first reported a position in Protalix BioTherapeutics in Q1 2018 and has held it in 9 quarters since.
  • 77 funds tracked by Wall St. Rank held Protalix BioTherapeutics as of Q3 2025.

Based on Wolverine Trading's 13F filing for Q3 2025, filed 14 Nov 2025.